Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug’s benefits for patients with mild or early Alzheimer’s. The nonbinding vote amounts to a ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

An experimental Alzheimer’s drug, donanemab, was endorsed by a U.S. Food and Drug Administration (FDA) advisory panel on Monday. Donanemab is designed to treat symptoms of early Alzheimer’s ...

Alzheimer's drug gets FDA panel's backing, setting the stage for broader use Eisai via AP, file This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their ...

On Friday, June 9, 2023, health advisers backed the full approval of the closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the ...

The drug, marketed by Eisai and Biogen, helped clear a brain plaque that is a hallmark of Alzheimer’s. The FDA panel reviewed more recent data from an 1,800-patient study in which people taking ...

WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early ...

WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early ...